Can Myfembree (relugolix + estradiol + norethisterone acetate) be started safely after Roux‑en‑Y gastric bypass surgery?

Myfembree After Gastric Bypass Surgery

Myfembree can be started safely after Roux-en-Y gastric bypass (RYGB) surgery, as it is an oral tablet formulation that does not rely on intestinal absorption for its hormonal components in the same way as nutrients, and the FDA labeling contains no specific contraindications related to bariatric surgery. However, timing and monitoring considerations are essential.

Key Clinical Considerations

Timing After Surgery

• Wait at least 12-18 months post-RYGB before initiating Myfembree 1. This recommendation aligns with standard guidance that pregnancy should be avoided during this critical weight loss period, and Myfembree is used for managing heavy menstrual bleeding from fibroids or endometriosis pain—conditions where fertility preservation matters.
• The rapid weight loss phase immediately post-surgery creates metabolic instability that could theoretically affect drug pharmacokinetics, though specific data for Myfembree is lacking.

Absorption and Pharmacokinetic Concerns

The critical question is whether RYGB affects absorption of Myfembree's three components:

Relugolix (GnRH antagonist): No specific data exists for post-RYGB patients, but as a small molecule oral medication, absorption should occur in the proximal small intestine which remains intact after RYGB 2.

Estradiol and Norethindrone: Research on similar oral contraceptive steroids post-RYGB is reassuring. A 2021 study found that levonorgestrel and ethinylestradiol pharmacokinetics were not clinically significantly affected by RYGB, with some patients actually showing higher AUC values 3. This suggests the estradiol and norethindrone components of Myfembree should be adequately absorbed.

Contraindications to Monitor

Myfembree is absolutely contraindicated in hepatic impairment or disease 2. This is critical because:

• Post-RYGB patients may develop hepatic complications
• The estradiol component increases exposure risk in hepatic impairment
• Check liver function tests before initiating Myfembree and monitor periodically

Practical Management Algorithm

1. Timing checkpoint:

   • Minimum 12-18 months post-RYGB
   • Weight stabilization achieved
   • No active surgical complications

2. Pre-treatment screening:

   • Comprehensive metabolic panel including liver function tests (ALT, AST, bilirubin, alkaline phosphatase)
   • Rule out pregnancy (Myfembree can cause early pregnancy loss) 2
   • Assess for other contraindications per FDA labeling

3. Contraception counseling:

   • Advise non-hormonal contraception during Myfembree treatment 2
   • Avoid hormonal contraceptives as they may decrease Myfembree efficacy and increase estrogen-related adverse events

4. Monitoring strategy:

   • Clinical response assessment at 2-3 months (menstrual bleeding patterns, pain scores)
   • If inadequate response, consider that malabsorption may be playing a role, though evidence suggests this is unlikely
   • Monitor for estrogen-related adverse effects (thromboembolism risk, though add-back therapy reduces this compared to GnRH agonist monotherapy)

Important Caveats

Micronutrient deficiencies: Post-RYGB patients commonly develop deficiencies in iron, B12, folate, calcium, and vitamin D 1. While these don't directly contraindicate Myfembree, they should be optimized as part of comprehensive care, especially since Myfembree may cause bone density loss (though the estradiol component mitigates this) 2.

No specific drug interaction data: The FDA labeling does not address bariatric surgery populations specifically 2. This represents a knowledge gap, but the available evidence on similar oral steroid hormones is reassuring 3.

Alternative delivery systems: If there were concerns about oral absorption (which current evidence does not support), non-oral options like the etonogestrel implant have been studied post-RYGB and maintain effective concentrations despite weight loss 4. However, Myfembree is only available as an oral formulation.

Clinical Efficacy Post-RYGB

Real-world data shows Myfembree is highly effective for fibroid-related heavy menstrual bleeding, with 94.7% response rates at 2 months and sustained efficacy in those continuing treatment 5. There is no reason to expect reduced efficacy in post-RYGB patients based on available pharmacokinetic data.

The bottom line: Proceed with Myfembree after the initial post-operative period (12-18 months), ensure normal liver function, and monitor clinical response as you would in any patient.